GENE ONLINE|News &
Opinion
Blog

BeiGene
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
Putting Patients First: The Quest to Make Anticancer Cell Therapy Accessible to All
2023-07-04
Cell Therapy as a Pillar of Future Therapeutics, an Interview with Alex Huang, Vice President and Head of Cell Therapy at BeiGene
2022-10-05
BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
2022-04-20
EMA Begins Review of BeiGene, Novartis’s PD-1 Antibody for Esophageal and Lung Cancer
2022-04-13
Novartis Licenses BeiGene’s Antibody for a Potential $2.8 Billion After Its Own Drug Disappoints
2021-12-21
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Brukinsa Receives EU Approval for the Treatment of Rare Lymphoma
2021-11-27
San Diego Startup Nabs $140 Million Following BeiGene, Kite Partnerships
2021-11-03
BeiGene Gets Its First Regulatory Nod in Australia for Rare Lymphoma
2021-10-08
FDA Accepts BeiGene’s BLA for Esophageal Cancer Drug
2021-09-14
BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
2021-09-06
Chinese Regulator Accepts BeiGene’s Tislelizumab sBLA for Nasopharyngeal Cancer
2021-08-23
China’s BeiGene to Build a Biologics Manufacturing Site in the US
2021-08-04
BITT’s TNFR2 Antagonist to Enter Clinical Trials In Collaboration with BeiGene
2021-02-20
1 2
LATEST
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
2024-06-19
Pie Medical Imaging announces enrollment completion of the FASTIII clinical trial
2024-06-18
Company Presentations at BIO 2024 Inspire Partnering
2024-06-14
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-06-13
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
2024-06-12
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
2024-06-12
BIO Releases DEI Survey in Partnership with Korn Ferry
2024-06-11
EVENT
Scroll to Top